What is it about?
Anejaculation is a rare cause of infertility and adversely affects the general sense of well-being and perception of sexual life satisfaction. Evidence to support effective and noninvasive treatment for this ejaculatory disorder is lacking. This study aimed to evaluate the efficacy and safety of midodrine (alpha(1)-adrenergic receptor agonist) for the treatment of organic anejaculation but not spinal cord injury (SCI).
Featured Image
Photo by SHTTEFAN on Unsplash
Perspectives
Anejaculation is defined as complete absence of antegrade or retrograde ejaculation. It is a rare disorder in men (1–4% of sexually active men) that can cause male factor infertility and considerable distress. Anejaculation can be classified as lifelong or acquired subtypes based on the developmental history. Ejaculation is a reflex comprising afferent and efferent pathways.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: Midodrine for the treatment of organic anejaculation but not spinal cord injury: a prospective randomized placebo-controlled double-blind clinical study, International Journal of Impotence Research, May 2009, Springer Science + Business Media,
DOI: 10.1038/ijir.2009.19.
You can read the full text:
Resources
Contributors
The following have contributed to this page
